NEW YORK, Sept. 26, 2013 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue: 2014 Opportunities in the US Clinical Chemistry and Immunodiagnostics Marketshttp://www.reportlinker.com/p01636157/2014-Opportunities-in-the-US-Clinical-Chemistry-and-Immunodiagnostics-Markets.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=In_Vitro_Diagnostic " 2014 Opportunities in the US Clinical Chemistry and Immunodiagnostics Markets" is a new strategic analysis of major business opportunities emerging in the US clinical chemistry and immunodiagnostic markets during the next five years. The report explores future trends in the US market; provides estimates of the specimen, test and sales volumes, as well as major suppliers sales and market shares; compares features of leading analyzers; profiles key competitors; and identifies specific product and marketing opportunities emerging during the next five years.The report provides five-year volume and sales forecasts for over 100 clinical chemistry, TDM, endocrine, cancer, immunoprotein and abused drug assays performed in hospitals, commercial laboratories, physician offices, and ambulatory care centers, including controls, calibrators and consumables. RationaleThe clinical chemistry and immunodiagnostic markets are undergoing significant transformation, caused by convergence of new and more stringent regulations; advances in diagnostic technologies, system engineering, automation, and IT; and intensifying competition. Some segments, like routine chemistry, are already resembling commodity markets, where product positioning and cost per test are more critical than underlying technology. This evolving marketplace creates exciting opportunities for a variety of new instruments, reagent systems, and auxiliary products, such as specimen preparation devices, controls, and calibrators. Strategic Recommendations- New product development opportunitieswith significant market appeal.- Alternative market penetration strategies.- Potential market entry barriers and risks. Competitive Assessments- Strategic assessments of major suppliers and emerging market entrants, including their sales, product portfolios, marketing tactics, collaborativearrangements and new products in R&D. - The companies analyzed in the report includeAbbott, AdnaGen, Agilent, Alere, Beckman Coulter/Danaher, Biomedical Diagnostics, bioMerieux, Bio-Rad, DiaSorin, Eiken, Fujirebio/Innogenetics, IL, Kyowa Medex, Ortho-Clinical Diagnotics, Roche, Siemens, Sysmex, Thermo Fisher, Tosoh, Wako, Wallac/PE. Tests Analyzed in the Report:- Routine Clinical ChemistryAlbumin, Alkaline Phosphatase, ALT/SGPT, Ammonia, Amylase, AST/SGOT, Bilirubin, Total, BUN (Blood Urea Nitrogen), Calcium, Cardio CRP, Carbon Dioxide/Bicarbonate, Chloride, Cholesterol, Creatine Kinase (CK), CK-MB, Creatinine, CRP, Ferritin, GGT, Glucose, HDL Cholesterol, Homocysteine, Iron, LDH, LDL Cholesterol, Magnesium, Phosphorus, Potassium, Protein, Total, Sodium, Triglycerides, Troponin, Uric Acid. - Therapeutic Drug Monitoring (TDM)Amikacin, Carbamazepine, Cyclosporin, Digoxin, Everolimus, Gentamicin, Levetiracetam, Lithium, Methotrexate, NAPA/Procainamide, Phenobarbital, Phenytoin, Quinidine, Sirolimus, Tacrolimus, Theophylline, Tobramycin, Topirimate, Valproic Acid, Vancomycin.- Endocrine FunctionCortisol, Estradiol, FSH, HCG, Gastrin, LH, Progesterone, PTH/IO PTH, Prolactin, T3, T3 Uptake, Free T3, T4, Free T4, TBG, Testosterone, Thyroglobulin Ab, TPO Ab, TSH. - Tumor Markers and Special ChemistryAFP, CA 15-3/27-29, CA 19-9, CEA, Ferritin, Follate (Folic Acid), Glycosylated Hemoglobin, HCG, 25-Hydroxy Vitamin D2 and D3, Occult Blood, PAP, PSA, Thyroglobulin, Vitamin B-12.- ImmunoproteinsC3, C4, Free Light Chains, Haptoglobin, IgA, IgE Specific, IgE Total, IgG, IgM, Immunofixation, Prealbumin, Protein Electrophoresis.- Drugs of AbuseAmphetamines, Barbiturates, Benzodiazepines, Cannabinoids/Marijuana, Cocaine, LSD, Methadone, Methaqualone, Opiates, Phencyclidine (PCP), Propoxyphene, Tricyclic Antidepressants.